Suppliers / Ind-Swift Laboratories

Ind-Swift Laboratories

India Updated 9 July 2026

Ind-Swift Laboratories is an API and finished-dose manufacturer based in India. It appears in 36 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with NPRA (MY), UZPHARM (UZ) and MINSA (CR). Its GMP standing is certified by EMA and CDSCO (India). Customs aggregates show $6.5M of exports covering 247 molecules to 27 destinations in 2025.

0
active US DMFs
0
valid CEPs
2
registered plants
36
filings across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
EU GMP
1 of 1 confirmed
Sources: EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Registered plants

Site FDA FEI
S.A.S Nagar, India Not on file
industrial growth centre samba, India Not on file

What they file, and where

Molecule Regulators Docs
Anastrozole SFDA (Saudi Arabia) 1
Atorvastatin SFDA (Saudi Arabia) 1
Clarithromycin SFDA (Saudi Arabia) 1
Ezetimibe SFDA (Saudi Arabia) 1
Fexofenadine SFDA (Saudi Arabia) 1
Ivabradine SFDA (Saudi Arabia) 1
Letrozole SFDA (Saudi Arabia) 1
Valganciclovir SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Anastrozole API Clarithromycin API Fexofenadine API Ivabradine API Letrozole API Nitazoxanide finished dose Pioglitazone finished dose Valganciclovir API Atorvastatin API Ezetimibe API

Filings and GMP by regulator

Regulator Filings GMP certificates
NPRA (MY) 19 None
UZPHARM (UZ) 11 None
MINSA (CR) 6 None
EMA None 6
CDSCO (India) None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $10.1M 30
2025 Not reported $6.5M 27
2024 Not reported $32.9M 51
2023 Not reported $112.0M 67

Export figures are customs aggregates. We do not publish the identity of any buyer.

Questions about Ind-Swift Laboratories

Does Ind-Swift Laboratories hold a US DMF or a CEP?
No active US drug master file or valid CEP is on record for Ind-Swift Laboratories. It does have 36 filings with 3 regulators, so it is registered, just not with the two strong registers buyers usually screen on.
Where does Ind-Swift Laboratories manufacture?
2 registered sites are on record, in India (S.a.s Nagar and Industrial Growth Centre Samba). Every site is listed on this page with the register it came from.
What does Ind-Swift Laboratories make?
8 molecules are on record against Ind-Swift Laboratories, including Anastrozole, Atorvastatin, Clarithromycin and Ezetimibe. Each links through to that molecule's full manufacturer list.
Which regulators recognise Ind-Swift Laboratories's GMP?
Current GMP certificates are on record from EMA and CDSCO (India). GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Ind-Swift Laboratories comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Comparable suppliers

Hetero shares 5 molecules Dr Reddy's Laboratories shares 4 molecules Synthimed Labs shares 4 molecules Cipla shares 3 molecules Apitoria Pharma shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts